All Inventions from NCI

  • Iodonium Analogs as Inhibitors of NADPH Oxidases and other Flavin Dehydrogenases and their Use for Treating Cancer...
    •
       Ref: E-116-2014 | Updated: Apr 14, 2021 | NCI
  • Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides
    •
       Ref: E-065-2019 | Updated: Apr 6, 2021 | NCI
  • Efficacious Fluorinated Cytidine Analog Cancer Therapeutic With Low Toxicity In Animal Studies
    •
       Ref: E-215-2018 | Updated: Apr 5, 2021 | NCI
  • Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19
    •
       Ref: E-253-2020 | Updated: Apr 5, 2021 | NCI
  • EGFRvIII Antibodies for the Treatment of Human Cancer
    •
       Ref: E-103-2019 | Updated: Mar 29, 2021 | NCI
  • New T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors
    •
       Ref: E-153-2016 | Updated: Mar 23, 2021 | NCI
  • T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias
    •    Ref: E-152-2020 | Updated: Mar 23, 2021 | NCI
  • T-Cell Receptors Targeting Epstein Barr Virus Latent Membrane Protein 2 for Treatment of Lymphomas and Epithelial...
    •
       Ref: E-121-2020 | Updated: Mar 23, 2021 | NCI
  • Tethered Interleukin-15 (IL-15)/IL-21 to Enhance T Cells for Cellular Therapy
    •
       Ref: E-068-2018 | Updated: Mar 23, 2021 | NCI
  • A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer...
    •
       Ref: E-108-2019 | Updated: Mar 10, 2021 | NCI
  • Non-invasive diagnostic and prognostic assay for early stage lung cancer
    •
       Ref: E-121-2013 | Updated: Mar 3, 2021 | NCI
  • 3-o-sulfo-galactosylceramide Analogs as Activators of Type II Natural Killer T (NKT) Cells to Reduce Cancer...
    •
       Ref: E-100-2018 | Updated: Feb 24, 2021 | NCI
  • Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs)
    •
       Ref: E-106-2015 | Updated: Feb 24, 2021 | NCI
  • T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy
    •
       Ref: E-175-2016 | Updated: Feb 11, 2021 | NCI
  • 3D Image Rendering Software for Biological Tissues
    •
       Ref: E-254-2012 | Updated: Jan 26, 2021 | NCI
  • A Specialized Tissue Collection Device for the Preservation and Transportation of Needle Biopsies
    •
       Ref: E-128-2017 | Updated: Jan 26, 2021 | NCI
  • T-cell Receptors (TCRs) Specific for p53 Mutants
    •
       Ref: E-173-2020 | Updated: Dec 28, 2020 | NCI
  • Small Molecule Inhibitors of Drug Resistant Forms of HIV-1 Integrase
    •
       Ref: E-093-2013 | Updated: Dec 23, 2020 | NCI
  • A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma
    •
       Ref: E-041-2014 | Updated: Dec 15, 2020 | NCI
  • A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain...
    •
       Ref: E-246-2014 | Updated: Dec 15, 2020 | NCI
  • A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma
    •
       Ref: E-174-2019 | Updated: Dec 15, 2020 | NCI
  • Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell...
    •
       Ref: E-018-2020 | Updated: Dec 15, 2020 | NCI
  • Reporter Plasmid to Identify Cancer Stem Cells
    •
       Ref: E-141-2011 | Updated: Dec 14, 2020 | NCI
  • Leucine Zipper-bearing Kinase (LZK) -Targeting Degraders and Methods of Use
    •
       Ref: E-163-2020 | Updated: Nov 30, 2020 | NCI
  • Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1)...
    •
       Ref: E-181-2018 | Updated: Nov 30, 2020 | NCI-CCR
  • RNASEH-Assisted Detection Assay for RNA
    •
       Ref: E-193-2020 | Updated: Nov 30, 2020 | NCI, CCR
  • T-Cell Therapy Against Patient-Specific Cancer Mutations
    •
       Ref: E-233-2014 | Updated: Oct 19, 2020 | NCI
  • Silica-Coated Nanodiamonds for Imaging and Delivery of Therapeutic Agents
    •
       Ref: E-175-2012 | Updated: Oct 6, 2020 | NCI
  • Use of the TP5 Peptide for the Treatment of Cancer
    •
       Ref: E-007-2019 | Updated: Oct 6, 2020 | NCI
  • Use of Acetalax for Treatment of Triple Negative Breast Cancer
    •
       Ref: E-041-2018 | Updated: Sep 25, 2020 | NCI-DTB
  • Platform to Enhance Anti-Tumor Immunity
    •
       Ref: E-053-2019 | Updated: Sep 22, 2020 | NCI
  • Detection of Novel Endocrine-Disrupting Chemicals in Water Supplies
    •
       Ref: E-269-2011 | Updated: Sep 16, 2020 | NCI
  • Fibroblast Growth Factor Receptor 4 (FGFR4) Monoclonal Antibodies and Methods of Their Use
    •    Ref: E-264-2015 | Updated: Sep 16, 2020 | NCI
  • Calcium (Ca2+) Flux-Dependent Method to Detect and Isolate Tumor Reactive T Cell Receptors (TCRs)
    •
       Ref: E-168-2018 | Updated: Sep 3, 2020 | NCI
  • Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)
    •
       Ref: E-061-2020 | Updated: Sep 3, 2020 | NCI
  • Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients
    •
       Ref: E-102-2020 | Updated: Sep 3, 2020 | NCI
  • T Cell Receptors (TCRs) Specific for Mutant p53
    •
       Ref: E-135-2019 | Updated: Sep 3, 2020 | NCI
  • Combination of Near Infrared Photoimmunotherapy Targeting Cancer Cells and Host-Immune Activation
    •
       Ref: E-113-2018 | Updated: Aug 24, 2020 | NCI
  • Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain...
    •
       Ref: E-063-2017 | Updated: Aug 24, 2020 | NCI
  • Compounds that Interfere with the Androgen Receptor Complex
    •
       Ref: E-162-2009 | Updated: Aug 17, 2020 | NCI
  • High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors
    •
       Ref: E-185-2019 | Updated: Aug 17, 2020 | NCI
  • Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice
    •
       Ref: E-096-2020 | Updated: Aug 17, 2020 | NCI
  • Therapeutic Immunotoxins with Increased Half-Life and Anti-Tumor Activity
    •
       Ref: E-179-2019 | Updated: Aug 17, 2020 | NCI
  • Cell Line for Production of Recombinant Human Tissue Inhibitor of Metalloproteinase-2
    •
       Ref: E-216-2017 | Updated: Aug 13, 2020 | NCI
  • Methods of Producing Thymic Emigrants from Induced Pluripotent Stem Cells
    •
       Ref: E-250-2016 | Updated: Aug 13, 2020 | NCI
  • Use of Cucurbitacins and Withanolides for the Treatment of Cancer
    •
       Ref: E-050-2010 | Updated: Aug 13, 2020 | NCI
  • Gene-based Diagnostic Predicts Patient Response to Cancer Immunotherapy
    •
       Ref: E-022-2017 | Updated: Aug 12, 2020 | NCI
  • Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters
    •
       Ref: E-132-2011 | Updated: Aug 12, 2020 | NCI
  • Diagnostic for Cancer of the Adrenal Glands and Adrenal Cortex
    •
       Ref: E-135-2012 | Updated: Aug 10, 2020 | NCI
  • Antisense Oligonucleotides against Cancer Cell Migration and Invasion
    •
       Ref: E-041-2020 | Updated: Jul 21, 2020 | NCI
  • Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment
    •    Ref: E-169-2018 | Updated: Jul 7, 2020 | NCI
  • Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus
    •
       Ref: E-125-2020 | Updated: Jul 7, 2020 | NCI
  • Improved CD22 Binders for Effective Immunotherapy Against Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL...
    •
       Ref: E-161-2018 | Updated: Jun 30, 2020 | NCI
  • Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell...
    •
       Ref: E-126-2019 | Updated: Jun 25, 2020 | NCI
  • Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in...
    •
       Ref: E-038-2019 | Updated: Jun 17, 2020 | NCI
  • Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276
    •
       Ref: E-145-2019 | Updated: Jun 17, 2020 | NCI
  • Mitotic Figures Electronic Counting Application for Surgical Pathology
    •
       Ref: E-097-2019 | Updated: Jun 17, 2020 | NCI
  • Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers
    •
       Ref: E-023-2019 | Updated: Jun 8, 2020 | NCI
  • Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in...
    •
       Ref: E-210-2018 | Updated: May 19, 2020 | NCI
  • Nanoparticle delivery of lung cancer therapeutic
    •
       Ref: E-159-2014 | Updated: May 18, 2020 | NCI
  • Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics
    •
       Ref: E-188-2017 | Updated: Apr 20, 2020 | NCI
  • Cancer Therapies Using Engineered Monomeric Fc Molecules
    •
       Ref: E-019-2012 | Updated: Apr 13, 2020 | NCI
  • Photoactivatable Lipid-based Nanoparticles as a Vehicle for Dual Agent Delivery
    •
       Ref: E-482-2013 | Updated: Apr 13, 2020 | NCI
  • Analogues of Withanolide E Sensitize Cancer Cells Toward Apoptosis
    •
       Ref: E-051-2016 | Updated: Apr 7, 2020 | NCI
  • Cancer Therapeutic based on Stimulation of Natural Killer T-cell Anti-tumor Activity
    •
       Ref: E-034-2010 | Updated: Apr 7, 2020 | NCI
  • Fully Human Antibodies and Antibody Drug Conjugates Targeting Tumor Endothelial Marker 8 (TEM8) for the Treatment...
    •
       Ref: E-344-2013 | Updated: Apr 7, 2020 | NCI
  • GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer
    •
       Ref: E-128-2009 | Updated: Apr 7, 2020 | NCI
  • Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of...
    •
       Ref: E-035-2013 | Updated: Apr 7, 2020 | NCI
  • Improved Production of Prenylated Protein in Insect Cells
    •
       Ref: E-009-2015 | Updated: Apr 7, 2020 | NCI
  • Inhibition of T Cell Differentiation and Senescence by Overexpression of Transcription Factor c-Myb
    •
       Ref: E-232-2015 | Updated: Apr 7, 2020 | NCI
  • Methods for Producing Stem Cell-Like Memory T Cells for Use in T Cell-Based Immunotherapies
    •
       Ref: E-174-2012 | Updated: Apr 7, 2020 | NCI
  • Multivalent Immunogenic Vaccines for Treating Prostate and Breast Cancer
    •
       Ref: E-047-2014 | Updated: Apr 7, 2020 | NCI
  • Nucleic Acid Nanoparticles for Triggering RNA Interference
    •
       Ref: E-156-2014 | Updated: Apr 7, 2020 | NCI
  • Therapeutic antibody-drug conjugates targeting CD56-positive cancers
    •
       Ref: E-221-2015 | Updated: Apr 7, 2020 | NCI
  • Topical Antibiotic for Faster Wound Healing
    •
       Ref: E-294-2011 | Updated: Apr 7, 2020 | NCI
  • Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy
    •    Ref: E-195-2018 | Updated: Apr 1, 2020 | NCI/Leidos
  • Reprogrammed Tumor Infiltrated Lymphocytes for Efficient Identification of Tumor-Antigen Specific T-Cell Receptors...
    •
       Ref: E-091-2019 | Updated: Mar 4, 2020 | NCI
  • T-Cell Therapy Against Patient-Specific Cancer Mutations
    •
       Ref: E-229-2014 | Updated: Feb 3, 2020 | NCI
  • Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded...
    •
       Ref: E-172-2017 | Updated: Jan 15, 2020 | NCI
  • High Affinity Monoclonal Antibodies Targeting Glypican-1
    •    Ref: E-028-2019 | Updated: Dec 10, 2019 | NCI
  • Design and Biological Activity of Novel Stealth Polymeric Lipid Nanoparticles for Enhanced Delivery of Hydrophobic...
    •
       Ref: E-154-2018 | Updated: Nov 19, 2019 | NCI
  • Synthetic Bacterial Nanoparticles as Drug and Vaccine Delivery Vehicles
    •
       Ref: E-098-2015 | Updated: Oct 2, 2019 | NCI
  • Efficient Methods to Prepare Hematopoietic Progenitor Cells in vitro for Therapeutic Use
    •
       Ref: E-132-2017 | Updated: Sep 18, 2019 | NCI
  • In vitro Generation of an Autologous Thymic Organoid from Human Pluripotent Stem Cells
    •
       Ref: E-133-2017 | Updated: Sep 18, 2019 | NCI
  • New Class of Immunotoxins with Extended Half-Life and High Anti-Tumor Activity
    •
       Ref: E-231-2017 | Updated: Aug 1, 2019 | NCI
  • Novel HPPK (Bacterial Protein) Inhibitors for Use as Antibacterial Agents
    •
       Ref: E-276-2016 | Updated: Aug 1, 2019 | NCI
  • A Method to Isolate Tumor Specific T-Cells or T-Cell Receptors from Peripheral Blood using In-vitro Stimulation of...
    •
       Ref: E-238-2017 | Updated: Jun 28, 2019 | NCI
  • Cancer Immunotherapies That Harness Pre-Existing Antiviral Immunity
    •
       Ref: E-167-2017 | Updated: Jun 28, 2019 | NCI
  • Conserved Elements Vaccine for HIV
    •    Ref: E-132-2012 | Updated: Jun 28, 2019 | NCI
  • Chimeric Antigen Receptor (CAR) that Targets Chemokine Receptor CCR4 and its Use in Treating Cancer
    •
       Ref: E-258-2016 | Updated: Jun 10, 2019 | NCI
  • High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin
    •
       Ref: E-040-2019 | Updated: May 15, 2019 | NCI
  • Nanoparticle-hydrogel Composite for Nucleic Acid Molecule Delivery
    •
       Ref: E-080-2018 | Updated: May 14, 2019 | NCI
  • Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent...
    •
       Ref: E-106-2017 | Updated: Apr 26, 2019 | NCI
  • Efficient Cell-Free Production of Papillomavirus Gene Transfer Vectors
    •
       Ref: E-298-2016 | Updated: Feb 12, 2019 | NCI
  • A Gene-Based Prognostic for Hepatocellular Carcinoma Patient Response to Adjuvant Transcatheter Arterial...
    •
       Ref: E-101-2016 | Updated: Jan 8, 2019 | NCI
  • Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma
    •
       Ref: E-211-2016 | Updated: Dec 19, 2018 | NCI
  • Polymeric Delivery Platform for Therapeutics
    •
       Ref: E-097-2017 | Updated: Dec 17, 2018 | NCI
  • siRNA Delivery Using Hexameric Tetrahedral RNA Nanostructures for Gene Silencing
    •
       Ref: E-075-2018 | Updated: Dec 14, 2018 | NCI
  • Transgenic Mouse Model of Human Basal Triple Negative Breast Cancer
    •
       Ref: E-191-2010 | Updated: Dec 14, 2018 | NCI
  • Treatment of Prostate Cancer Using Anti-androgen Small Molecules
    •
       Ref: E-015-2011 | Updated: Nov 27, 2018 | NCI

    Pages


    Displaying 1 - 100 of 243

    Office of Technology Transfer, Office of Intramural Research, National Institutes of Health

    6011 Executive Blvd, Suite 325, Rockville, MD 20852 | Phone: 301-496-7057